Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Proteome Sciences Plc LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.28 -6.51% 4.02 3.70 4.34 - 8,925 16:35:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 4.7 -0.0 0.1 80.4 12

Proteome Sciences Share Discussion Threads

Showing 152176 to 152200 of 152200 messages
Chat Pages: 6088  6087  6086  6085  6084  6083  6082  6081  6080  6079  6078  6077  Older
DateSubjectAuthorDiscuss
22/10/2020
10:13
And again,what is wrong with him.????
peverill
22/10/2020
08:34
Good morning all.
tom barnaby
22/10/2020
07:48
Perverill Anything ia wise vs your guff that if the CEO is not posting RNSs to help you feel better, she cannot be doing anything Do you really expect any excitement when they do update?
stocktastic
21/10/2020
20:03
Good evening Wrighty41.
tom barnaby
21/10/2020
17:59
Thanks Colin. 2021 should be exciting times for shareholders buying at these levels. W41
wrighty41
21/10/2020
17:55
Proteome Sciences TMT technology used in research to identify Covid-19 biomarkers ================================================================================= 20 October 2020 Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19 The COVID-19 pandemic is a global public health crisis. However,little is known about the pathogenesis and biomarkers of COVID-19. Herein, we profiled host responses to COVID-19 by performing plasma proteomics of a cohort of COVID-19 patients including non-survivors and survivors recovered from mild or severe symptoms, and uncovered numerous COVID-19-associated alterations of plasma proteins. We developed a machine learning-based pipeline to identify 11 proteins as biomarkers and a set of biomarker combinations, which were validated by an independent cohort and accurately distinguished and predicted COVID-19 outcomes. ---a total of 62 plasma samples were categorized into 7 batches and separately subjected to tandem mass tag (TMT) labeling (Table S2). For each batch, individual samples were labeled with TMT 11-plex reagents, and a pooling mixture of all the 62 samples was included and labeled as a standard control to eliminate the batch effect.--- Discussion The pandemic of COVID-19 has been one of the worst public health crises. It is of high priority to identify biomarkers that can monitor and predict the development of the disease and understand its pathogenesis. For this purpose, we conducted proteomics to profile plasma protein alterations in response to COVID-19 under different conditions, and identified 11 host proteins and a set of biomarker combinations that can serve as biomarkers by using the machine learning-based pipeline POC-19 developed by us. These biomarkers can classify and predict the outcomes of COVID-19. HTTPS://www.sciencedirect.com/science/article/pii/S1074761320304490
colinhy
21/10/2020
17:50
I see he is still dishing out his wisdom.
peverill
21/10/2020
15:39
Ha, thanks elpirata. Time flies hey! Point still stands though Nothing embarrassing Golly on your scale of embarrassment!
stocktastic
21/10/2020
15:11
BOL! How embarrassing.
tom barnaby
21/10/2020
13:32
Financial highlights: · Proteomics services revenues increased 71% to £0.60m (H1 2019: £0.35m) · TMT® reagent sales and royalties down 8% to £1.27m (H1 2019: £1.37m) · Total revenues increased 9% to £1.90m (H1 2019: £1.74m) · Gross profit increased 11% to £1.07m (H1 2019: £0.96m) · Costs increased 11% to £2.22m (H1 2019: £1.99m) · Loss before tax was £0.48m (H1 2019: £0.41m)
dominiccummings
21/10/2020
13:28
when the H1 results will be out soon anyway FAO stocktastic https://tinyurl.com/y6rd5bfr ;-))) !!
elpirata
21/10/2020
13:13
"Morning all,still no sin of Mariola,strange for a new CEO to be so elusive when she runs the greatest gift to Proteomics on the planet.!!!" Perverill It remains possible that she is focused on selling business services - you would not be seeing that - rather than spending time on a pointless RNS just to make you feel happy, when the H1 results will be out soon anyway
stocktastic
21/10/2020
12:43
"Several sources of positive newsflow to come in the following weeks and months, including stroke trial news and commercial licencing from Randox and possibly Galaxy." "News No News Available in the last month for PRM" Years? Decades?
jeffian
21/10/2020
11:39
#87808 I should imagine she is so busy taking fauxn calls from 'the stable' that she hasnt had time to start work yet.
tom barnaby
21/10/2020
11:38
Good morning monte1.
tom barnaby
21/10/2020
11:38
Good morning peverill.
tom barnaby
21/10/2020
10:32
Mariella https://youtu.be/WPvLFDRufGk
monte1
21/10/2020
10:21
Morning all,still no sin of Mariola,strange for a new CEO to be so elusive when she runs the greatest gift to Proteomics on the planet.!!!
peverill
21/10/2020
10:19
I’ll put the bunting out.
monte1
21/10/2020
10:01
We've had a trade, I note.
tom barnaby
21/10/2020
09:59
Good morning Tom Barnaby
monte1
21/10/2020
09:58
Good morning monte1.
tom barnaby
21/10/2020
09:58
Good morning colinhy.
tom barnaby
21/10/2020
09:48
Good morning and thanks Colinhy. I can’t help thinking that yer c&p’s are becoming ever less frequent - are you sure you are still putting in the hours? Wouldn’t like to think that ye are slacking.
monte1
21/10/2020
09:46
October 20 2020 Emerging mass spectrometry-based proteomics methodologies for novel biomedical applications With the latest advances for TMT, researchers can now even label up to 16 distinct samples with different TMT tags, pool them, and subsequently analyze them all in a single acquisition. Multiplexing can be increased to even higher levels in anticipation of newer reagents in the future. Isobaric labeling strategies TMT workflows and the various improved generations of reagents have greatly improved MS multiplexing capabilities for relative quantification of different experimental conditions. The significant reduction in the cost per acquisition make it more likely that TMT will be adopted in clinical tests or patient-specifi;c oncological mapping. Ultimately, in the future, we envision widespread implementation clinical MS and the development of personalized medicine employing these MS-based proteomics technologies. HTTPS://portlandpress.com/biochemsoctrans/article/doi/10.1042/BST20191091/226710/Emerging-mass-spectrometry-based-proteomics HTTPS://portlandpress.com/biochemsoctrans/article-pdf/doi/10.1042/BST20191091/895335/bst-2019-1091c.pdf
colinhy
Chat Pages: 6088  6087  6086  6085  6084  6083  6082  6081  6080  6079  6078  6077  Older
ADVFN Advertorial
Your Recent History
LSE
PRM
Proteome S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201022 22:41:50